The Cancer Genome Atlas (TCGA) project has divided gastric cancer into four main subgroups by their molecular characteristics, including Epstein-Barr virus (EBV), microsatellite instability (MSI), genomically stable (GS) and chromosome instability (CIN). However, the relationships between clinical significance and four molecular subtypes are still awaiting further elucidation. Therefore, researchers analyzed the data from two respective cohorts that include 267 gastric cancer patients in the US and 432 gastric patients in South Korea. They aim to understand the relationship between the clinical benefits and molecular subtypes of gastric cancer. The results showed that the EBV subtype exhibited the best recurrence-free survival (RFS) and overall survival (OS), indicating the best prognosis. However, the GS subtype showed the worst PFS and OS, indicating the worst prognosis. Furthermore, patients with the CIN subtype showed the greatest benefit from adjuvant chemotherapy with a three-year RFS rate of 58.7 % for patients receiving chemotherapy compared with 33.5% for patients not receiving chemotherapy. These findings indicate that the four main molecular subtypes in gastric cancer have the potential to be utilized in clinical settings in the future, especially in selecting the most suitable treatment for each patient.
2. Publication: Clin Cancer Res. 2017 Jul 26. doi: 10.1158/1078-0432.CCR-16-2211.